Q-Line Biotech Annual General Meeting
Q-Line Biotech has sent a letter to shareholders with bounced emails, providing links to the Annual Report and 16th AGM Notice, scheduled for September 30, 2026.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Q-Line Biotech has sent a letter to shareholders with bounced emails, providing links to the Annual Report and 16th AGM Notice, scheduled for September 30, 2026.
Q-Line Biotech Limited has submitted its Annual Report for the financial year 2025-26. The full document is accessible via the provided company website link.
Q-Line Biotech approved the Board's Report, notice for the 16th AGM, and re-appointment of two Whole Time Directors and the Cost Auditor.
Q-Line Biotech Limited has re-appointed M/s. P S P & Associates as Cost Auditors for a 12-month term.
Q-Line Biotech amended its license agreement with Boule Medical AB, Sweden. The revision includes a 25% reduction in license/royalty costs effective from July 2026.
Q-Line Biotech Ltd reported revenue from operations of ₹197.9 Cr (-8.6% YoY) and net profit of ₹34.4 Cr (+290.9% YoY) for H2 FY26.